ESPE Abstracts

Introduction: Recombinant human growth hormone (rhGH) has been pivotal in growth hormone (GH) therapies for children since its approval for paediatric growth hormone deficiency (PGHD). The recent introduction of long-acting growth hormone (LAGH) represents a further advancement in GH therapy, demonstrating equal efficacy compared to daily GH with the added benefit of decreased injection frequency. Clinical trials have underscored the effectiveness and safety o...